Wunderle, Marius
Pretscher, Jutta
Brucker, Sara Y.
Volz, Bernhard
Hartmann, Arndt
Fiessler, Cornelia
Hein, Alexander
Häberle, Lothar
Jud, Sebastian M.
Lux, Michael P.
Janni, Wolfgang
Loehberg, Christian R.
Hartkopf, Andreas D.
Walter, Christina B.
Baake, Gerold
Fridman, Alexander
Malter, Wolfram
Wuerstlein, Rachel
Harbeck, Nadia
Hoffmann, Oliver
Kümmel, Sherko
Martin, Bernhard
Thomssen, Christoph
Graf, Heiko
Wolf, Christopher
Bayer, Christian M.
Hack, Carolin C.
Almstedt, Katrin
Gass, Paul
Heindl, Felix
Brodkorb, Tobias F.
Nabieva, Naiba
Lindner, Christoph
Kolberg, Hans-Christian
Krabisch, Petra
Weigel, Michael
Steinfeld-Birg, Dieter
Kohls, Andreas
Brucker, Cosima
Schulz, Volker
Fischer, Gunnar
Pelzer, Volker
Wallwiener, Diethelm
Rack, Brigitte
Fehm, Tanja
Rody, Achim
Maass, Nicolai
Beckmann, Matthias W.
Fasching, Peter A.
Rauh, Claudia
Funding for this research was provided by:
Novartis Pharma GmbH Germany
Article History
Received: 25 October 2018
Accepted: 20 December 2018
First Online: 2 January 2019
Compliance with ethical standards
:
: A Hartmann received honoraria from BMS, Roche, MSD, Novartis, AstraZeneca, NanoString, and BioNTech and funding from NanoString, BioNTech, and Janssen-Cilag. MPL received honoraria from Pfizer, Roche, MSD, Hexal, Novartis, AstraZeneca, Celgene, Eisai, Medac, and Thieme for advisory boards, lectures, and travel support. WJ received research grants from Novartis. ADH participated on advisory boards for Novartis. RW participated on advisory boards for Novartis, AstraZeneca, Pfizer, and Lilly. SK participated on advisory boards for Roche/Genentech, Genomic Health, Novartis, AstraZeneca, Amgen, Celgene, SOMATEX, Daiichi Sankyo, Puma Biotechnology, pfm medical, Pfizer, and MSD Oncology and received funding from Roche and Daiichi Sankyo. CT received honoraria from Amgen, AstraZeneca, Celgene, Genomic Health, Lilly, NanoString, Novartis, Pfizer, Puma, and Roche for lectures and advisory boards. CCH received honoraria from Roche. PG received honoraria from Novartis, Roche, and PharmaMar. NN received honoraria from Janssen-Cilag and Novartis. HCK received honoraria from Carl Zeiss Meditec, TEVA, Theraclion, Novartis, Amgen, AstraZeneca, Pfizer, Janssen-Cilag, GSK, LIV Pharma, Roche, and Genomic Health and is stock owner of Theraclion and Phaon Scientific GmbH. MW participated on advisory boards for Novartis, Roche, Pfizer, and Celgene. BR participated on advisory boards for Novartis and Roche and received funding from AstraZeneca, Chugai, Lilly, Novartis, Janssen-Cilag, and Sanofi Aventis. TF participated on advisory boards for Novartis, Roche, AstraZeneca, Pfizer, and Daiichi Sankyo. MWB’s institution received research grants from Novartis. PAF received honoraria from Novartis, Roche, Pfizer, and Amgen. CR received honoraria from Novartis, Roche, Celgene, and Eisai. All remaining authors have declared no conflicts of interest.
: Approval for the study was obtained from the ethics committee of the Faculty of Medicine at Friedrich Alexander University of Erlangen-Nuremberg and all of the relevant local ethics committees. All procedures were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Written informed consent was obtained from the patients as part of the inclusion criteria before they entered the study.